DUBLIN, June 9, 2014 /PRNewswire/ -- Actavis plc
(NYSE: ACT) (the "Company") today announced that it has extended
the expiration date of its offer to guarantee the outstanding debt
securities listed in the table below (the "FRX Notes") of Forest
Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of
the existing registration rights obligations with respect to each
of those debt securities (the "Consent Solicitations"). The
Consent Solicitations were originally scheduled to expire at
5:00 p.m., New York City time, on June 6, 2014. The expiration date of the
Consent Solicitations has been extended until 5:00 p.m., New York
City time, on June 12,
2014.
Series of FRX
Notes
|
Aggregate
Principal
Amount
Outstanding
|
4.375% Senior Notes
due 2019
|
U.S. $1.05
billion
|
4.875% Senior Notes
due 2021
|
U.S. $750
million
|
5.00% Senior Notes
due 2021
|
U.S. $1.2
billion
|
As of the time of this news release, a majority of holders of
each series of FRX Notes have delivered consents pursuant to the
Consent Solicitations.
Forest has engaged D.F. King
& Co., Inc. to act as the Information and Tabulation Agent for
the Consent Solicitations. Holders wishing to certify that they are
Eligible Holders and be eligible to receive a copy of the Consent
Solicitation Statement should go to www.dfking.com/frx and complete
the eligibility form. Requests for assistance may be directed to
D.F. King & Co., Inc. at (212)
269-5550 or (800) 967-4617 (toll free) or frx@dfking.com.
This press release is for informational purposes only and does
not constitute an offer of the ACT Guarantees or a solicitation of
consents. The information in this press release is subject in
all respects to the terms and conditions set forth in the Consent
Solicitations Statement, dated May 22,
2014 (as may be amended or supplemented from time to
time). The Consent Solicitations do not constitute an offer
of the ACT Guarantees in any jurisdiction in which, or to or from
any person to or from whom, it is unlawful to make such offer under
applicable securities or "blue sky" or other laws. None of
Actavis, Forest, their respective boards of directors, the trustee,
the Information and Tabulation Agent, the solicitation agent or any
of their respective affiliates makes any recommendation as to
whether holders should tender, or refrain from tendering, all or
any portion of the principal amount of their FRX Notes pursuant to
the Consent Solicitations.
The Consent Solicitations are being made solely pursuant to the
Consent Solicitation Statement, which more fully set forth and
govern the terms and conditions of the Consent Solicitation. The
Consent Solicitation Statement contains important information and
should be read carefully before any decision is made with respect
to the Consent Solicitations.
About Actavis
Actavis plc (NYSE: ACT) is a global, integrated specialty
pharmaceutical company focused on developing, manufacturing and
distributing generic, brand and biosimilar products. Actavis
has global headquarters in Dublin,
Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA.
Actavis develops and manufactures generic, brand, branded
generic, legacy brands and Over-the-Counter (OTC) pharmaceutical
products and has commercial operations in approximately 60
countries. The Company's North American branded
pharmaceuticals business is focused principally in the Women's
Health, Urology, Gastroenterology and Dermatology therapeutic
categories with a strong pipeline of products in various stages of
development. Actavis also has a portfolio of five biosimilar
products in development in Women's Health and Oncology.
Actavis Global Operations has more than 30 manufacturing and
distribution facilities around the world, and includes Anda, Inc.,
a U.S. pharmaceutical product distributor.
For press release and other company information, visit Actavis'
Web site at http://www.actavis.com. Information on our Web
site is not incorporated into, and does not form a part of, this
press release.
Important Information for Investors and Shareholders
This communication does not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of
any vote or approval, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. In connection with the
proposed merger between Actavis and Forest, Actavis has filed with
the Securities and Exchange Commission (the "SEC") a registration
statement on Form S-4 containing a joint proxy statement of Actavis
and Forest that also constitutes a prospectus of Actavis. The
registration statement was declared effective by the SEC on
May 2, 2014. Each of Actavis
and Forest has mailed to its stockholders or shareholders the proxy
statement/prospectus. In addition, each of Actavis and Forest
has filed and will file with the SEC other documents with respect
to the proposed transaction. INVESTORS AND SECURITY HOLDERS
OF ACTAVIS AND FOREST ARE URGED TO READ THE DEFINITIVE JOINT PROXY
STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR TO BE FILED WITH
THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and
security holders will be able to obtain free copies of the
registration statement and the definitive joint proxy
statement/prospectus and other documents filed with the SEC by
Actavis and Forest through the website maintained by the SEC at
http://www.sec.gov. Copies of the documents filed with the SEC
by Actavis will be available free of charge on Actavis' internet
website at www.actavis.com or by contacting Actavis' Investor
Relations Department at (862) 261-7488. Copies of the documents
filed with the SEC by Forest will be available free of charge on
Forest's internet website at www.frx.com or by contacting
Forest's Investor Relations Department at (212) 224-6713.
Participants in the Merger Solicitation
Actavis, Forest, their respective directors and certain of their
executive officers and employees may be considered participants in
the solicitation of proxies in connection with the proposed
transaction. Information regarding the persons who may, under the
rules of the SEC, be deemed participants in the solicitation of the
Actavis and Forest shareholders in connection with the proposed
merger will be set forth in the joint proxy statement/prospectus
when it is filed with the SEC. Information about the directors and
executive officers of Forest is set forth in its proxy statement
for its 2013 annual meeting of stockholders, which was filed with
the SEC on July 8, 2013 and certain
of its Current Reports on Form 8-K. Information about the directors
and executive officers of Actavis is set forth in its proxy
statement for its 2014 annual meeting of shareholders, which was
filed with the SEC on March 28, 2014
and certain of its Current Reports on Form 8-K. Additional
information regarding the participants in the proxy solicitations
and a description of their direct and indirect interests, by
security holdings or otherwise, is contained in the joint proxy
statement/prospectus filed with the above-referenced registration
statement on Form S-4 and other relevant materials to be filed with
the SEC when they become available.
Actavis Cautionary Statement Regarding Forward-Looking
Statements
Statements contained in this communication that refer to
Actavis' estimated or anticipated future results, including
estimated synergies, or other non-historical facts are
forward-looking statements that reflect Actavis' current
perspective of existing trends and information as of the date of
this communication. Forward looking statements generally will be
accompanied by words such as "anticipate," "believe," "plan,"
"could," "should," "estimate," "expect," "forecast," "outlook,"
"guidance," "intend," "may," "might," "will," "possible,"
"potential," "predict," "project," or other similar words, phrases
or expressions. Such forward-looking statements include, but are
not limited to, statements about the benefits of the Forest
acquisition, including future financial and operating results,
Actavis' or Forest's plans, objectives, expectations and intentions
and the expected timing of completion of the transaction. It is
important to note that Actavis' goals and expectations are not
predictions of actual performance. Actual results may differ
materially from Actavis' current expectations depending upon a
number of factors affecting Actavis' business, Forest's business
and risks associated with acquisition transactions. These factors
include, among others, the inherent uncertainty associated with
financial projections; restructuring in connection with, and
successful closing of, the Forest acquisition; subsequent
integration of the Forest acquisition and the ability to recognize
the anticipated synergies and benefits of the Forest acquisition;
the ability to obtain required regulatory approvals for the
transaction (including the approval of antitrust authorities
necessary to complete the acquisition), the timing of obtaining
such approvals and the risk that such approvals may result in the
imposition of conditions that could adversely affect the combined
company or the expected benefits of the transaction; the ability to
obtain the requisite Forest and Actavis shareholder approvals; the
risk that a condition to closing of the Forest acquisition may not
be satisfied on a timely basis or at all; the failure of the
proposed transaction to close for any other reason; risks relating
to the value of the Actavis shares to be issued in the transaction;
the anticipated size of the markets and continued demand for
Actavis' and Forest's products; the impact of competitive products
and pricing; access to available financing (including financing for
the acquisition or refinancing of Actavis or Forest debt) on a
timely basis and on reasonable terms; the risks of fluctuations in
foreign currency exchange rates; the risks and uncertainties
normally incident to the pharmaceutical industry, including product
liability claims and the availability of product liability
insurance on reasonable terms; the difficulty of predicting the
timing or outcome of pending or future litigation or government
investigations; periodic dependence on a small number of products
for a material source of net revenue or income; variability of
trade buying patterns; changes in generally accepted accounting
principles; risks that the carrying values of assets may be
negatively impacted by future events and circumstances; the timing
and success of product launches; the difficulty of predicting the
timing or outcome of product development efforts and regulatory
agency approvals or actions, if any; market acceptance of and
continued demand for Actavis' and Forest's products; costs and
efforts to defend or enforce intellectual property rights;
difficulties or delays in manufacturing; the availability and
pricing of third party sourced products and materials; successful
compliance with governmental regulations applicable to Actavis' and
Forest's facilities, products and/or businesses; changes in the
laws and regulations affecting, among other things, pricing and
reimbursement of pharmaceutical products; changes in tax laws or
interpretations that could increase Actavis' consolidated tax
liabilities; the loss of key senior management or scientific staff;
and such other risks and uncertainties detailed in Actavis'
periodic public filings with the Securities and Exchange
Commission, including but not limited to Actavis plc's Annual
Report on form 10-K for the year ended December 31, 2013, Quarterly Report on form 10-Q
for the quarter ended March 31, 2014
and Current Report on form 8-K filed on May
20, 2014 and from time to time in Actavis' other investor
communications. Except as expressly required by law, Actavis
disclaims any intent or obligation to update or revise these
forward-looking statements.
CONTACTS:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Charlie
Mayr
(862) 261-8030
David Belian
(862) 261-8141
Logo -
http://photos.prnewswire.com/prnh/20130124/NY47381LOGO
SOURCE Actavis plc